Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. An update on the drug safety of treating erectile dysfunction

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Cardiovascular safety and benefits of GLP-1 receptor agonists

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kenya A Costa-Dookhan
  • Sri Mahavir Agarwal
  • Araba Chintoh
  • Veronica N Tran
  • Nicolette Stogios
  • Bjørn H Ebdrup
  • Sanjeev Sockalingam
  • Tarek K Rajji
  • Gary J Remington
  • Dan Siskind
  • Margaret K Hahn
Vis graf over relationer

Introduction: Clozapine remains the most effective antipsychotic for treatment-refractory schizophrenia. However, ~40% of the patients respond insufficiently to clozapine. Clozapine's effects, both beneficial and adverse, have been proposed to be partially attributable to its main metabolite, N-desmethylclozapine (NDMC). However, the relation of the clozapine to norclozapine ratio (CLZ:NDMC; optimally defined as ~2) to clinical response and metabolic outcomes is not clear.Areas covered: This narrative review comprehensively examines the clinical utility of the CLZ:NDMC ratio to reduce metabolic risk and increase treatment efficacy. The association of the CLZ:NDMC ratio with changes in psychopathology, cognitive functioning, and cardiometabolic burden will be explored, as well as adjunctive treatments and their effects.Expert opinion: The literature suggests a positive association between the CLZ:NDMC ratio and better cardiometabolic outcomes. Conversely, the CLZ:NDMC ratio appears inversely associated with better cognitive functioning but less consistently with other psychiatric domains. The CLZ:NDMC ratio may be useful for predicting and monitoring cardiometabolic adverse effects and optimizing potential cognitive benefits of clozapine. Future studies are required to replicate these findings, which if substantiated, would encourage examination of adjunctive treatments aiming to alter the CLZ:NDMC ratio to best meet the needs of the individual patient, thereby broadening clozapine's clinical utility.

TidsskriftExpert Opinion on Drug Safety
Udgave nummer1
Sider (fra-til)43-57
Antal sider15
StatusUdgivet - jan. 2020

ID: 59086612